Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.58 |
| ▸ | TK2 | O00142 | 2/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.53 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CDA | P32320 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656890 | 1.00 | PYGM (0.58) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL25385069 | 0.89 | PYGM (0.61) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2580905 | 0.89 | PYGM (0.61) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL263751 | 0.82 | DNPH1 (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14946378 | 0.82 | DNPH1 (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL9465821 | 0.82 | DNPH1 (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14853793 | 0.82 | DNPH1 (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL263750 | 0.82 | DNPH1 (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14929135 | 0.82 | DNPH1 (0.71) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL7107741 | 0.82 | PYGM (0.55) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124598-A1 | Antibiotic compounds | EC TECHNOLOGY, LLC (US) | 2005-06-09 | — | — | US | claimed |
| WO-2003051314-A2 | ANTIBIOTIC COMPOUNDS | MEDALLION BIOMEDICAL, LLC (US) | 2003-06-26 | — | — | WO | claimed |
| US-7179907-B2 | Antibiotic compounds | SOMALOGIC OPERATING CO. INC. | 2007-02-20 | — | — | US | disclosed |
| US-20050124598-A1 | Antibiotic compounds | EC TECHNOLOGY, LLC (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2003051314-A2 | ANTIBIOTIC COMPOUNDS | MEDALLION BIOMEDICAL, LLC (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124598-A1 | Antibiotic compounds | RNGTT, BCDIN3D, COASY | PYGM 2510/4885TK2 2110/4885SLC28A1 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.